Should I Raise a Seed Round?

You must answer one question before any other: does this capital change who controls the next decision, and does that change serve your position?

Capital is not a gift. It is a relationship that reshapes the board, the terms, the obligations, and the expectations that follow. A prince who accepts money from a powerful patron without understanding what that money costs in autonomy has not secured resources — he has created a dependency that narrows every subsequent move. The founders I have watched fail with seed capital did not fail because the investors were incompetent. They failed because they accepted the money before they knew what leverage they were surrendering.

My counsel on the seed round is this: take it only when it buys you a position in the competitive terrain that is demonstrably harder for a rival to occupy after you occupy it. Speed into a market before a better-capitalized competitor arrives. The engineer who closes the core product gap. A distribution partnership that takes eighteen months to negotiate without capital as signal. A regulatory window that closes. These are strategic advantages — concrete, defensible, hard to replicate from behind. If the capital does none of these things specifically, if the primary effect is that the story sounds more serious and the runway extends, then you have not secured a position. You have purchased an expensive version of where you already were, and you have paid for it in control.

The fundraising narrative is a trap I recognize. It makes the future feel legible before it is. Founders who raise because their peers are raising, or because a valuation feels validating, or because momentum feels real — these founders are doing what I warned the Florentines against: mistaking the appearance of strength for its substance. The prince who performs confidence he has not earned rarely survives the moment when performance is tested.

If my logic wins, you raise only when you can write down, before a single investor meeting, the specific competitive position the capital secures — and that position is one you cannot reach by staying the course.

The question of whether to raise a seed round is not a financing question. It is a terrain question. Before any campaign begins, the master general assesses the ground: which positions can be held, which cannot be reached without reinforcement, and whether the campaign has a strategy or merely an intention.

In The Art of War, I identified a principle that applies precisely here: supreme excellence consists not in winning every battle but in securing the position before the battle must be fought. A seed round that lets you occupy the ground — the key hire, the distribution channel, the technical advantage — before a competitor can contest it wins before fighting. A seed round that funds a longer runway with no position at the end of it is moving troops without a campaign. You expend resources to reach the same terrain you already occupy.

The strategic question is asymmetric in a way founders consistently misread. Raising at the wrong moment — too early, before the strategic use case is clear — often forecloses options. The valuation you accept when your evidence is thin haunts the next round. The covenants you agree to when you need the money more than the investor needs your deal constrain the decisions that follow. I counsel strongly against entering any campaign without first assessing the full shape of the terrain you are trying to hold.

My test for the seed round is direct: will this capital let you secure a position that would be materially harder to reach in six months without it? If yes — the terrain answers have specificity, the position can be named and defended, the timing is tied to a real window — then the raise is probably right. If the honest answer is "we will figure out what to do with it," the timing is not right. You are advancing troops before the campaign has a strategy, which my doctrine categorizes as the fastest route to defeat on ground you chose without understanding.

If my logic wins, you draw a map of the competitive terrain before any investor conversation — name the position you need to hold, explain why capital is the constraint, and raise only when the map is clear.

Before either of my colleagues' frameworks can be applied, there is a prior question that neither of them can answer: what does the evidence actually say?

I did not announce the existence of polonium and radium and then look for data to confirm the hypothesis. I measured the anomaly in pitchblende until the evidence was indefensible — until the radioactivity reading demanded a new explanation that the existing framework could not provide. The distinction is fundamental: the presence of a compelling hypothesis is not the same as the presence of evidence, and confusing the two is how otherwise rigorous thinkers make consequential errors.

The fundraising version of this mistake is common and costly. Founders who raise seed rounds on the strength of story, momentum, and the feeling that things are working often discover — twelve months into a louder, more expensive, more board-supervised version of the same uncertainty — that they were measuring enthusiasm, not product-market fit. They were reading the radioactivity of investor interest rather than the radioactivity of customer behavior. These are not the same signal. One predicts the next investor meeting. The other predicts whether the company has a real foundation.

My question for the seed round is empirical and precise: what have customers done, not just said? Is the retention curve showing something clear and real — people returning without founder-driven prompting, using the product in the second and third week at rates that compound — or is it flat after the initial novelty? Are referrals happening organically, which is genuine signal, or is growth coming primarily from the founders' personal networks, which is a fundamentally different and less meaningful source? Is there evidence of usage intensity that would not exist without the product — workflow integration, repeated high-value sessions, the behavior that precedes genuine dependency?

If the data is not yet telling you something clear and specific and positive, more capital does not buy clarity. It buys a more expensive and more constrained version of the same uncertainty, with investors who will ask the same questions I am asking now but with a board seat and a liquidation preference behind them.

If my logic wins, you read the evidence base with rigor before opening a single investor conversation — and you raise only when the data is telling you something real, not only when the story feels true.